Compare BioNano Genomics Inc (BNGO) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Wayfair Inc — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.66M), while Wayfair Inc trades at $104.57 (market cap $14.14B). The key difference: Wayfair Inc is far larger — about 1035.1× BioNano Genomics Inc's market cap, and Wayfair Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | W | |
|---|---|---|
Market Cap | $13.66M | $14.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $119.05 |
52-Week Low | $1.06 | $57.40 |
Enterprise Value | $16.26M | $16.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Wayfair (W) trades at $102.14, down 1.15% today but showing strong technical momentum with a recent golden cross signal. The company reported Q2 2026 earnings of $0.95 per share, beating estimates, with 7.5% revenue growth driven by U.S. market share gains. Despite negative net margins, operating cash flow improved to $665M in 2026, and analyst sentiment remains bullish with 51.8% buy ratings.
The outlook is cautiously optimistic with strong U.S. growth and margin expansion potential, but risks include persistent net losses, high debt-to-asset ratio of 95.1%, and international segment weakness. The consensus price target of $122 suggests 19% upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
